Genentech Pays US$120 M Upfront for UCB’s Tau-targeting Antibody UCB0107

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 8 (Table of Contents)

Published: 4 Aug-2020

DOI: 10.3833/pdr.v2020.i8.2554     ISSN: 1756-7874

Section: Research & Development



Broadening its presence in the CNS space, Roche’s Genentech has licensed the worldwide rights to develop and commercialise UCB’s tau-targeting antibody UCB0107 for the treatment of Alzheimer’s disease...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details